Clinical Trials in New York

Showing 18541-18560 of 22,668 trials

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00660816

RATIONALE: Pemetrexed disodium and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving pemetrexed disodium or docetaxel together with erlotinib hydrochloride is more effective than giving pemetrexed disodium or docetaxel alone in treating non-small lung cancer. PURPOSE: This randomized phase II trial is studying how well giving pemetrexed disodium or docetaxel together with or without erlotinib hydrochloride works in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Lung Cancer

Case Comprehensive Cancer Center46 participantsStarted Jan 2008

Detroit, Michigan, United States • New York, New York, United States • Cleveland, Ohio, United States +10 more locations

COMPLETEDNA< 1 mile

Mobile Insulin Titration Intervention

NCT01879579

The purpose of this pilot study is to determine whether text message (and phone) communication can be effectively utilized to adjust long-acting insulin, compared to standard practice.

Diabetes Mellitus

NYU Langone Health61 participantsStarted Jun 2013

New York, New York, United States

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Mobile Insulin Titration Intervention

Find Trials by Condition in New York

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations

Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions

Optimizing Hand Rehabilitation Post-Stroke Using Interactive Virtual Environments

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

Ph IIA Study (SOC +/- NS5B)

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

A Study of AZD4901 in Females With Polycystic Ovary Syndrome